| 参与单位名称及 人员姓名 | 参与公司 2022 年度业绩说明会的广大投资者。 | | --- | --- | | 时 间 | 2023 年 4 月 26 日 下午 15:00-17：00 | | 地 点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | 上市公司接待人 | 董事长穆竟伟女士、总经理王国明先生、独立董事李整妮女士、董事会 | | 员姓名 | 秘书任立旺先生、财务总监张育琴女士 一、本次活动介绍 | | | 公司于 2023 年 4 月 26 日（星期三）下午 15 点至 17 点在全景网举 行 2022 年度业绩说明会。本次年度业绩说明会采用网络远程的方式举 | | | 行。投资者就公司未来发展、生产经营情况等方面进行了问答互动交流， 主要内容如下： | | 投资者关系活动 | 二、互动交流 | | | 1、穆董，我想了解一下，为什么优欣定的研发，凯宝到目前为止 | | 主要内容介绍 | 才使用了 1500 万的资金投入？是遇到什么困难了吗？ | | | 投资者您好，该项目按照研发时间节点正在进行中，感谢您的关注！ | | | 2、极泽的业绩是否符合并入公司财 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥459,387,490.40, representing a 33.61% increase compared to ¥343,817,802.76 in the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥80,178,876.36, a 39.11% increase from ¥57,636,350.93 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥74,483,881.60, reflecting a 30.24% increase compared to ¥57,190,694.89 in the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.0767, up 39.20% from ¥0.0551 in the same quarter last year[5] - Total operating revenue for Q1 2023 reached ¥459,387,490.40, an increase of 33.7% compared to ¥343,817,802.76 in the same period last year[22] - Net profit for Q1 2023 was ¥80,118,147.25, representing a 40.2% increase from ¥57,142,663.02 in Q1 2022[23] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥353,887,256.07, compared to ¥165,979,475.93 in Q1 2022, indicating a significant increase of about 113.1%[24] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥4,757,637,196.49, an increase of 11.70% from ¥4,259,271,286.92 at the end of the previous year[5] - Total liabilities reached ¥642,779,893.90, compared to ¥498,240,511.29 at the start of the year, an increase of 29.0%[20] - The company's equity attributable to shareholders rose to ¥4,115,640,086.51 from ¥3,761,752,830.44, an increase of 9.4%[20] Cash Flow - The company's cash flow from operating activities for Q1 2023 was ¥79,310,976.85, down 8.90% from ¥87,056,121.17 in the same period last year[5] - Cash inflows from operating activities totaled ¥485,001,700.80 in Q1 2023, compared to ¥427,893,178.34 in Q1 2022, marking an increase of about 13.3%[27] - The net cash flow from operating activities for Q1 2023 was ¥79,310,976.85, a decrease from ¥87,056,121.17 in Q1 2022, representing a decline of approximately 8.0%[27] - The net cash flow from investment activities increased by 350.96% compared to the same period last year, primarily due to a reduction in the purchase of financial products[13] - The net cash flow from financing activities decreased by 100.00% compared to the same period last year, mainly due to a reduction in cash inflows from financing activities[13] - The net increase in cash and cash equivalents grew by 2115.61% compared to the same period last year, attributed to a decrease in cash outflows from investment activities[13] - The total cash and cash equivalents at the end of Q1 2023 reached ¥582,156,672.45, up from ¥287,816,363.17 at the end of Q1 2022, reflecting an increase of approximately 102.2%[27] Research and Development - Research and development expenses increased by 140.34% year-on-year, indicating a significant investment in new product development[11] - Research and development expenses increased significantly to ¥24,076,351.54, compared to ¥10,017,656.02 in the previous year, reflecting a growth of 140.1%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 79,143, with no preferred shareholders having restored voting rights[13] - The top three shareholders hold a combined 38.93% of the total shares, with Mu Jingwei holding 16.06%, Zhang Yanqi holding 15.37%, and Xinxiang Kaiyi Industrial Co., Ltd. holding 7.50%[13] - The total number of restricted shares at the end of the period is 129,152,731, all of which are subject to executive lock-up[16] Subsidiaries - The company established two new subsidiaries: Henan Yishen Pharmaceutical Chemical Co., Ltd. with a registered capital of RMB 20 million and Henan Kaibao Pharmaceutical Co., Ltd. with a registered capital of RMB 1 million[17] - The company holds 90% of the shares in Henan Yishen Pharmaceutical Chemical Co., Ltd., which was registered on February 28, 2023[17] - The company holds 100% of the shares in Henan Kaibao Pharmaceutical Co., Ltd., which obtained its pharmaceutical business license on March 29, 2023[17] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 8.98%, up from 5.31% in the same period last year, indicating improved profitability[5] - The company experienced a 75.55% increase in accounts payable, primarily due to increased material and other payables[11] - Total operating costs amounted to ¥364,517,922.48, up 35% from ¥270,153,211.19 in Q1 2022[23] - The company reported a significant increase in sales expenses, which totaled ¥236,460,016.10, compared to ¥179,111,174.54 in the previous year, reflecting a growth of 32.1%[23] - Cash and cash equivalents at the end of Q1 2023 were ¥715,115,006.57, up from ¥694,690,170.16 at the beginning of the year, indicating a growth of 2.0%[20] Audit Status - The report for Q1 2023 was not audited[28]

Financial Performance - The company's operating revenue for 2022 was ¥1,118,850,525.24, representing a 1.66% increase compared to ¥1,100,578,391.34 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥190,804,507.54, a 36.18% increase from ¥140,113,625.43 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥177,594,537.24, up 41.02% from ¥125,934,898.50 in 2021[19]. - The net cash flow from operating activities increased by 198.56% to ¥376,418,583.05 from ¥126,078,156.45 in 2021[19]. - Basic earnings per share for 2022 were ¥0.1824, a 36.12% increase from ¥0.1340 in 2021[19]. - Total assets at the end of 2022 were ¥4,259,271,286.92, a 26.92% increase from ¥3,355,816,769.77 at the end of 2021[19]. - The net assets attributable to shareholders at the end of 2022 were ¥3,761,752,830.44, reflecting a 23.54% increase from ¥3,044,914,136.88 in 2021[19]. - The weighted average return on equity for 2022 was 20.69%, an increase of 2.98% from 17.71% in 2021[19]. - The company reported a significant increase in quarterly revenues, with Q4 2022 revenue reaching ¥318,837,460.39[21]. - The company's cash generated from operating activities for 2022 was ¥87,056,121.17, compared to ¥48,538,228.03 in 2021, indicating a significant increase[22]. Product and Market Development - The company’s main product, Tanreqing injection, is recognized as a key medication in the treatment of various major infectious diseases, including COVID-19[34]. - The company has established three major product lines: respiratory, cardiovascular, and digestive fields, with key products including Tanreqing injection/capsule and Qishen capsule[35]. - The subsidiary Kaibao Health focuses on product development and market promotion in the health technology sector, leveraging traditional Chinese medicine[36]. - The company has established a strong competitive edge in the respiratory system medication market, particularly during the COVID-19 pandemic[34]. - The company is actively exploring new markets and product applications, including the development of new food raw materials like "in vitro cultivated bear bile powder"[44]. - The company has initiated an expansion and automation upgrade of its extraction production line to enhance capacity and ensure market supply[44]. Research and Development - Continuous R&D efforts are being made for the main product Tanreqing, including clinical evidence and real-world data studies to support academic promotion[44]. - The company has established a joint R&D center with Shanghai Jiao Tong University to enhance technology development and product innovation[36]. - The company is committed to enhancing its research and development capabilities in response to national policies promoting traditional Chinese medicine[30][32]. - The company is focusing on R&D innovation, increasing investment in research and development to enhance core competitiveness and achieve significant progress in core product series development[46]. - The Phlegm-Heat Clearing series products are undergoing various clinical trials, with the Phlegm-Heat Clearing Oral Liquid in Phase III clinical research and the Phlegm-Heat Clearing Capsule in Phase II clinical research[47]. Corporate Governance and Compliance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and enhancing information disclosure practices[114]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure[117]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation directly to performance[121]. - The internal audit department is responsible for overseeing financial reporting and internal controls, ensuring the safety and integrity of company assets[124]. - The company maintains independence from its controlling shareholder in operations, finance, and management, ensuring autonomous business capabilities[126]. - The company has implemented a comprehensive internal control system to mitigate risks and enhance operational efficiency[124]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities with a processing capacity of 1,000 tons per day to ensure stable compliance with discharge standards[179]. - The company invested CNY 585,400 in environmental governance and protection in 2022, and paid CNY 27,800 in environmental protection tax[186]. - The company donated a total of CNY 1,500,000 to various charitable organizations and local communities during the reporting period[187][188]. - The company actively participates in poverty alleviation and rural revitalization projects, supporting education and infrastructure development in targeted areas[189]. - The company has developed emergency response plans for environmental incidents, including hazardous chemical accidents and abnormal operating conditions[184]. Financial Management and Investment - The company plans to use RMB 78,145,870 of the raised funds, including RMB 14 million for permanent working capital and RMB 18,305,000 for the modernization of traditional Chinese medicine products[85]. - The company reported a total of RMB 1,439,490,000 in financial assets at the end of the period, with significant changes in fair value[78]. - The company has not engaged in derivative investments during the reporting period[83]. - The company’s total financial liabilities remained at zero, indicating no debt obligations[78]. - The company has not sold any significant assets during the reporting period[101]. Employee Management and Development - The total number of employees at the end of the reporting period is 1,380, with 507 in the parent company and 873 in major subsidiaries[159]. - The company has established a competitive compensation system based on market principles, including fixed salaries, performance bonuses, and comprehensive welfare benefits[160]. - The company plans to enhance employee training in 2023, focusing on sales, knowledge skills, and management training to improve overall capabilities[161]. - The company has implemented a training system to foster a learning-oriented environment, enhancing employee skills and knowledge[161]. Future Outlook and Strategy - The company aims to enhance its core product technology innovation and quality, focusing on the modernization of traditional Chinese medicine as a long-term development direction[104]. - In 2023, the company plans to strengthen quality control and risk management, aiming for "zero defects" in product sampling and improving operational efficiency through information technology[105]. - The company will optimize market promotion by innovating academic promotion methods and expanding product market development and application[106]. - The company faces industry policy risks due to ongoing healthcare reforms, which may impact the pharmaceutical sector significantly[108].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：300039 证券简称：上海凯宝 公告编号：2023-017 上海凯宝药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 特此公告。 上海凯宝药业股份有限公司 董事会 上海凯宝药业股份有限公司（以下简称"公司"）《2022 年年度报告》及其摘要 于 2023 年 4 月 19 日在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露。 为了使广大投资者更深入、全面的了解公司生产经营情况及未来发展规划，公 司定于 2023 年 4 月 26 日（星期三）下午 15：00-17：00 在全景网举行 2022 年度业 绩网上说明会。本次说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次网上说明会的人员有：董事长穆竟伟女士，董事、总经理王国明先生， 独立董事李整妮女士，董事会秘书任立旺先生，财务总监张育琴女士。 为充分尊重投资者、 ...

证券代码：300039 证券简称：上海凯宝 记录编号：2015-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------|---------------------------|--------------|----------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | 投资者关 | □媒体采访 □业绩说明会 | | | | 系 | □ 新闻发布会 □路演活动 | | | | 活动类别 | | | □现场参观 □其他 （请文字说明其他活动内容） | | | | | | | 参与单位 名称及人 | | | 证券日报——周一叶 甘玲玉 上海申辰——冯超 | | 员姓名 | | | | | | | | | | 时 间 | 2015 年 04 月 | 28 日 上午 | 14：30 -15：30 | | 地 点 | 公司二楼会议室 | | | | 上市公司 | | | | | 接待人员 | 董秘： ...

证券代码：300039 证券简称：上海凯宝 记录编号：2015-003 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |----------|---------------------------|-----------------|-------|----------------------------------------------------------|----------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | | | 投资者关 | □媒体采访 □业绩说明会 | | | | | | 系 | □ 新闻发布会 □路演活动 | | | | | | 活动类别 | | | | □现场参观 □其他 （请文字说明其他活动内容） | | | | | | | | | | | | | | 信达澳银基金——曾国富 张培培 安信证券---于洋 国信证券 --- | 万明亮 | | | 东方证券 ---- | 黄文锋 红象投 ...